Intarcia 'on cloud nine' after $210m private funding for once-yearly exenatide implant
This article was originally published in Scrip
Executive Summary
Intarcia Therapeutics raised a whopping $210 million in private financing in concurrent transactions to fund Phase III development of its type 2 diabetes product candidate ITCA 650, which consists of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide delivered continuously by a matchstick-sized, subcutaneously-implanted osmotic pump.
You may also be interested in...
Drug Rejection Hearings Are Having A Moment At US FDA
With Intarcia's request, the rarely used mechanism could now produce two hearings this year, but outcomes of the few other times the process has been undertaken should not generate a lot of confidence for sponsors that this a path that they want to go down.
A Year And A Half After Giving Up On TAK-721, Takeda Seeks Approval In EoE
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.
Finance Watch: ReCode’s Series B Mega-Round Grows Again With $50m Boost
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.